Wegovy pill vs Foundayo: which weight-loss pill fits your life?
Two once-daily GLP-1 pills are now approved. One loses a bit more weight, the other is far easier to take. Here is how to think about the trade-off.
For years, the most effective weight-loss medicines came as a weekly injection. That changed in the past year. The FDA approved the Wegovy pill from Novo Nordisk in December 2025 and Foundayo from Eli Lilly in April 2026. Both are taken by mouth once a day, and both work on the same appetite hormone as the injections, GLP-1.
They are not the same pill in two colors, though. They differ in what is inside, how you take them, how much weight people lost and what they cost. This guide walks through each difference in plain terms.
The short answer
The Wegovy pill produced more weight loss in its main trial and carries a proven heart benefit on its label, but it comes with a strict morning routine. Foundayo produced less weight loss, but you can take it any time of day, with or without food. If you can stick to a morning ritual, the Wegovy pill gives you more. If your mornings are unpredictable, Foundayo is much easier to live with.
| Wegovy pill | Foundayo | |
|---|---|---|
| Made by | Novo Nordisk | Eli Lilly |
| What is inside | Semaglutide, the same medicine as the Wegovy injection | Orforglipron, a new kind of small-molecule GLP-1 drug |
| How to take it | Every morning on an empty stomach, small sip of water, then wait 30 minutes | Once a day at any time, with or without food |
| Average weight loss | 16.6% over 64 weeks | 12.4% over 72 weeks |
| Nausea | 46.6% | 33.7% |
| Stopped due to side effects | 6.9% | 10.3% |
| Heart benefit on the label | Yes | No |
Weight loss counts people who kept taking the medication in the main trials (OASIS 4 and ATTAIN-1). Counting everyone who started, the figures are 13.6% and 11.1%.
What is actually inside each pill
The Wegovy pill contains semaglutide, the exact medicine in the Wegovy and Ozempic injections. Semaglutide is a peptide, a small protein, and the stomach normally breaks proteins down before they can do anything. To get around that, the tablet includes a helper ingredient that protects the medicine and lets a small amount pass through the stomach wall. That trick only works when the stomach is nearly empty, which is why the rules are so strict.
Foundayo takes a different route. Orforglipron is not a peptide at all. It is a small, sturdy molecule, closer to an ordinary tablet medicine, that still switches on the GLP-1 receptor. Because digestion does not destroy it, food and water make no difference.
The daily routine is the real difference
With the Wegovy pill, you take the tablet first thing in the morning on an empty stomach with no more than half a glass of plain water (about 4 oz). Then you wait at least 30 minutes before eating, drinking coffee or taking other pills. Skip the wait and less medicine gets absorbed.
With Foundayo, there are no such rules. Take it with breakfast, at lunch or before bed. For people who work early shifts, travel a lot or already take other morning medicines, that freedom matters more than it sounds.
How much weight did people lose?
In its main trial, people taking the top dose of the Wegovy pill lost 16.6% of their body weight on average over 64 weeks, roughly the same as the Wegovy injection. On Foundayo's top dose, people lost 12.4% over 72 weeks. For someone starting at 100 kg, that is about 17 kg versus 12 kg.
These numbers come from two separate trials with different people and lengths, so the gap is a guide rather than a precise head-to-head result. And they are averages: some people lose much more, some much less.
Side effects
Both pills cause the familiar GLP-1 stomach side effects: nausea, vomiting, diarrhea and constipation, mostly while the dose is being increased. Nausea was reported more often with the Wegovy pill (46.6% vs 33.7%), but more people stopped Foundayo because of side effects (10.3% vs 6.9%). Both carry the same warning as the injections about a rare type of thyroid tumor, and neither is for people with a personal or family history of medullary thyroid cancer.
The heart question
Semaglutide has been shown in a large trial to lower the risk of heart attack, stroke and heart-related death in people who already have heart disease. That benefit is written on the Wegovy pill's label. Foundayo does not have that on its label yet. If you have heart disease, this is worth raising with your doctor.
What they cost
Both companies sell the pills directly to people paying out of pocket. As of autumn 2026, the lowest dose of each starts at around $149 a month, and higher doses cost roughly $299 to $349 a month, depending on the dose and the program. People with commercial insurance may pay much less with a manufacturer savings card. Prices change often, so check NovoCare and LillyDirect for the current figures.
Which one should you ask about?
The Wegovy pill may suit you if you want the most weight loss you can get from a pill, you have heart disease, or you already have a calm morning routine. Foundayo may suit you if you want the simplest possible routine, take several other morning medicines, or have tried the Wegovy pill's rules and found them hard to keep. Either way, the right choice depends on your health history, so use this as a starting point for a conversation with a doctor.
For full trial numbers, see the Oral GLP-1 section of our comparison.
This article is general information, not medical advice. Figures come from published trial results and company announcements available on October 10, 2026. Talk to a licensed clinician before starting, stopping or changing any medication.